Study identifies gene linked to chemotherapy resistance in prostate cancer

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Study maps complex interplay between cells, metabolism, and immunity in breast cancer lymph node metastasis

A recent integrative analysis of single-cell sequencing and single-cell spatial mapping of lymph node metastasis in breast cancer reveals novel mechanisms of the metabolic-immune interaction that ...

Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
Labroots

New Immunotherapy Targets Early-Stage Prostate Cancer

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Brits urged to look for 3 key prostate cancer symptoms to ensure early diagnosis

The NHS has stated that cases of the deadly condition have a higher chance of being 'cured' if detected early.
Targeted Oncology

PEACE-2: No Benefit, Higher Toxicity With Cabazitaxel in Prostate Cancer

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.
CURE

Cabazitaxel Adds No Survival Benefit in High-Risk Prostate Cancer

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...
The Malaysian Reserve

Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in ...

Results from Blue Earth Diagnostics’ head-to-head study have been published in the European Journal of Nuclear Medicine and Molecular Imaging and were just presented at the 2026 ASCO Genitourinary ...
Medindia

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Oncology Media Relations oncology_media_relations@its.jnj.com   Investor contact: Jessica Margevich investor-relations@its.jnj.com ...
PNAS

TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers

This study proposes a solution to the critical challenge of rapid and accurate intraoperative assessment of surgical margins and metastatic lymph nodes during early breast cancer surgery. We introduce ...